Smoking cessation may deteriorate glycemic control in diabetic patients
the ONA take:
Patients with type 2 diabetes mellitus who quit smoking see a temporary deterioration in glycemic control that may last up to three years, according to a recent study published in The Lancet Diabetes & Endocrinology.
Researchers led by Deborah Lycett, PhD, of Convetry University studied primary care records of 10,692 adult smokers with type 2 diabetes mellitus over six years to see if there was any association between diabetes control and smoking cessation.
They found that in 3,131 people (29 percent) who had quit for at least one year, HbA1c increased by 2.3 mmol/mol before gradually decreasing as abstinence continued.
During the same amount of time, 5,831 (55 percent) of patients who continually smoked experienced a more gradual increase in HbA1c. Those who quit saw comparable HbA1c levels with continual smokers after three years of quitting.
“Knowing that deterioration in blood glucose control occurs around the time of stopping smoking helps to prepare those with diabetes and their clinicians to be proactive in tightening their glycemic control during this time,” Dr. Lycett concluded.
Patients with type 2 diabetes mellitus who quit smoking see a temporary deterioration in glycemic control that may last up to three years.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Dual HER2 Blockade With an AI Effective in Advanced Breast Cancer
- Loperamide Regimen May Reduce Diarrhea in Neratinib-treated Patients
- PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab
- Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer
- Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|